Investors Urged to Consider Class Action Against Altimmune, Inc. Prior to Deadline

Altimmune, Inc. Class Action Notice

Levi & Korsinsky, LLP has put Altimmune, Inc. investors on alert regarding an upcoming class action lawsuit. This lawsuit seeks to hold the company accountable for losses related to a series of alleged securities frauds occurring between August 10, 2023, and June 25, 2025.

Background of the Case

On June 26, 2025, Altimmune released a press statement announcing the topline results from its Phase 2b MASH trial involving Pemvidutide, which aims to treat Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH). Prior to this release, the company had raised expectations significantly, but the analysis unveiled disappointing results, suggesting that they had failed to achieve the necessary statistical significance for the primary endpoint concerning fibrosis reduction.

Despite expectations of improved outcomes, the trial ultimately revealed a strong placebo effect that swayed the results, leading to a dramatic stock price plunge. Following the disclosure of these findings, Altimmune’s stock nosedived from $7.71 per share on June 25 to just $3.61 per share the next day, indicating a staggering decrease of over 53%.

Next Steps for Investors

Investors who suffered financial losses during this timeframe have until October 6, 2025, to act. Those who wish to lead the class action must submit a request to the court by this deadline, although participation as a class member without leading is still an option for potential compensation. The firm ensures that there are no costs incurred for class members to participate in the litigation, and eligibility for recovery does not depend on assuming the lead plaintiff role.

Why Choose Levi & Korsinsky?

With two decades of experience, Levi & Korsinsky has built a solid reputation for successfully advocating on behalf of wronged shareholders, reclaiming hundreds of millions of dollars. The firm ranks consistently among the top securities litigation firms in the U.S., boasting a dedicated team of specialists in complex securities litigation.

For any inquiries regarding this lawsuit or participation in the class action, affected Altimmune investors can reach out directly to attorney Joseph E. Levi at (212) 363-7500 or via email at email protected]. Additionally, further information can be found at [Levi & Korsinsky's web page.

This class action highlights the importance of investor awareness regarding the actions of public companies, reinforcing the role of legal recourse in ensuring accountability. Investors must stay vigilant and informed, especially when faced with significant market fluctuations and corporate disclosures that may impact their financial interests.